Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.59 |
| ▸ | MPO | P05164 | 3/20 | 0.59 |
| ▸ | HTR2C | P28335 | 2/20 | 0.59 |
| ▸ | HTR6 | P50406 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | HTR1D | P28221 | 1/20 | 0.59 |
| ▸ | HTR1B | P28222 | 1/20 | 0.59 |
| ▸ | HTR7 | P34969 | 1/20 | 0.59 |
| ▸ | CTSK | P43235 | 1/20 | 0.59 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30776660 | 1.00 | HTR2A (0.59) | HTR2ATAAR1MPOHTR2CHTR6 | |
| SCHEMBL28264220 | 0.89 | MPO (0.47) | HTR2ATAAR1MPOHTR2CHTR6 | |
| SCHEMBL8655960 | 0.87 | MPO (0.46) | HTR2ATAAR1MPOHTR2CHTR6 | |
| SCHEMBL2245672 | 0.84 | AHR (0.50) | HTR2ATAAR1MPOHTR2CHTR6 | |
| SCHEMBL29364833 | 0.84 | AHR (0.50) | HTR2ATAAR1MPOHTR2CHTR6 | |
| Hydrochloric Acid SCHEMBL3869136 | 0.82 | AHR (0.48) | HTR2ATAAR1MPOHTR2CHTR6 | |
| SCHEMBL29443976 | 0.81 | AHR (0.47) | HTR2AHTR2CHTR6CYP3A4HTR1B | |
| SCHEMBL6536568 | 0.81 | AHR (0.47) | HTR2ATAAR1MPOHTR2CHTR6 | |
| SCHEMBL31663380 | 0.81 | AHR (0.47) | HTR2ATAAR1MPOHTR2CHTR6 | |
| SCHEMBL28787727 | 0.81 | AHR (0.52) | HTR2ATAAR1MPOHTR2CHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108993496-B | Preparation method of ropinirole intermediate for treating dyskinesia | 山东第一医科大学(山东省医学科学院) | 2021-01-15 | — | — | CN | claimed |
| CN-117586233-A | Preparation and application of N- [ (1H-indol-4-yl) alkyl ] benzamide compound | 沈阳药科大学 | 2024-02-23 | — | — | CN | disclosed |
| US-20230102879-A1 | TRNA SYNTHETASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-03-30 | — | — | US | disclosed |
| US-11446298-B2 | Pyrimidine derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-09-20 | — | — | US | disclosed |
| US-11261201-B2 | TRNA synthetase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-03-01 | — | — | US | disclosed |
| EP-3625223-B1 | PYRIMIDINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-08-11 | — | — | EP | disclosed |
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2021-02-25 | — | — | US | disclosed |
| CN-108993496-B | Preparation method of ropinirole intermediate for treating dyskinesia | 山东第一医科大学(山东省医学科学院) | 2021-01-15 | — | — | CN | disclosed |
| US-20200108068-A1 | PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2020-04-09 | — | — | US | disclosed |
| EP-3625223-A1 | PYRIMIDINE DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2020-03-25 | — | — | EP | disclosed |
| EP-2044056-A1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | Novartis Ag (CH) | 2009-04-08 | — | — | EP | disclosed |
| EP-1478363-B1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LAB (US) | 2009-01-14 | — | — | EP | disclosed |
| EP-1660455-B1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LAB (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2008006583-A1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | disclosed |
| US-7230118-B2 | Process for the preparation of ropinirole | URQUIMA S.A. (ES) | 2007-06-12 | — | — | US | disclosed |
| US-7230118-B2 | Process for the preparation of ropinirole | URQUIMA S.A. (ES) | 2007-06-12 | — | — | US | disclosed |
| US-20070032540-A1 | Process for the preparation of ropinirole | URGUIMA S.A. (ES) | 2007-02-08 | — | — | US | disclosed |
| US-20070032540-A1 | Process for the preparation of ropinirole | URGUIMA S.A. (ES) | 2007-02-08 | — | — | US | disclosed |
| EP-0164633-A2 | Indole derivatives | MERCK PATENT GmbH (DE) | 1985-12-18 | — | — | EP | disclosed |
| US-4378368-A | Use of 4-(2-di-n-propylaminoethyl)indole or a salt thereof as a presynaptic dopamine autoreceptor stimulant | PURDUE RESEARCH FOUNDATION (US) | 1983-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | TRMT1, AARS1, GARS1 | HTR2A 3576/4885TAAR1 2359/4885MPO 1383/4885 |
| US-20070032540-A1 | Process for the preparation of ropinirole | PRLHR, COMT, DRD4 | HTR2A 130/4885TAAR1 250/4885MPO 578/4885 |
| US-20230102879-A1 | TRNA SYNTHETASE INHIBITORS | TRMT1, AARS1, GARS1 | HTR2A 3576/4885TAAR1 2359/4885MPO 1383/4885 |
| US-11446298-B2 | Pyrimidine derivatives | PTGER1, PTGER4, PTGER2 | HTR2A 439/4885TAAR1 734/4885MPO 4592/4885 |
| US-20200108068-A1 | PYRIMIDINE DERIVATIVES | PTGER1, PTGER4, PTGER2 | HTR2A 439/4885TAAR1 734/4885MPO 4592/4885 |
| US-11261201-B2 | TRNA synthetase inhibitors | TRMT1, AARS1, GARS1 | HTR2A 3576/4885TAAR1 2359/4885MPO 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.